Randomized trial of the effect of four second-generation antipsychotics and one first-generation antipsychotic on cigarette smoking, alcohol, and drug use in chronic schizophrenia

Somaia Mohamed, Robert A. Rosenheck, Haiqun Lin, Marvin Swartz, Joseph Patrick McEvoy, Scott Stroup

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

No large-scale randomized trial has compared the effect of different second-generation antipsychotic drugs and any first-generation drug on alcohol, drug and nicotine use in patients with schizophrenia. The Clinical Antipsychotic Trial of Intervention Effectiveness study randomly assigned 1432 patients formally diagnosed with schizophrenia to four second-generation antipsychotic drugs (olanzapine, risperidone quetiapine, and ziprasidone) and one first-generation antipsychotic (perphenazine) and followed them for up to 18 months. Secondary outcome data documented cigarettes smoked in the past week and alcohol and drug use severity ratings. At baseline, 61% of patients smoked, 35% used alcohol, and 23% used illicit drugs. Although there were significant effects of time showing reduction in substance use over the 18 months (all p < 0.0001), this study found no evidence that any antipsychotic was robustly superior to any other in a secondary analysis of data on substance use outcomes from a large 18-month randomized schizophrenia trial.

Original languageEnglish (US)
Pages (from-to)486-492
Number of pages7
JournalJournal of Nervous and Mental Disease
Volume203
Issue number7
DOIs
StatePublished - Jul 1 2015

Fingerprint

Antipsychotic Agents
Schizophrenia
Smoking
Alcohols
Pharmaceutical Preparations
olanzapine
Perphenazine
Risperidone
Street Drugs
Nicotine
Tobacco Products
Clinical Trials

Keywords

  • Alcohol dependence
  • Drug dependence
  • Schizophrenia
  • Second-generation antipsychotics
  • Smoking

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Randomized trial of the effect of four second-generation antipsychotics and one first-generation antipsychotic on cigarette smoking, alcohol, and drug use in chronic schizophrenia. / Mohamed, Somaia; Rosenheck, Robert A.; Lin, Haiqun; Swartz, Marvin; McEvoy, Joseph Patrick; Stroup, Scott.

In: Journal of Nervous and Mental Disease, Vol. 203, No. 7, 01.07.2015, p. 486-492.

Research output: Contribution to journalArticle

@article{d9d620d803574fd5b538fbd633e54399,
title = "Randomized trial of the effect of four second-generation antipsychotics and one first-generation antipsychotic on cigarette smoking, alcohol, and drug use in chronic schizophrenia",
abstract = "No large-scale randomized trial has compared the effect of different second-generation antipsychotic drugs and any first-generation drug on alcohol, drug and nicotine use in patients with schizophrenia. The Clinical Antipsychotic Trial of Intervention Effectiveness study randomly assigned 1432 patients formally diagnosed with schizophrenia to four second-generation antipsychotic drugs (olanzapine, risperidone quetiapine, and ziprasidone) and one first-generation antipsychotic (perphenazine) and followed them for up to 18 months. Secondary outcome data documented cigarettes smoked in the past week and alcohol and drug use severity ratings. At baseline, 61{\%} of patients smoked, 35{\%} used alcohol, and 23{\%} used illicit drugs. Although there were significant effects of time showing reduction in substance use over the 18 months (all p < 0.0001), this study found no evidence that any antipsychotic was robustly superior to any other in a secondary analysis of data on substance use outcomes from a large 18-month randomized schizophrenia trial.",
keywords = "Alcohol dependence, Drug dependence, Schizophrenia, Second-generation antipsychotics, Smoking",
author = "Somaia Mohamed and Rosenheck, {Robert A.} and Haiqun Lin and Marvin Swartz and McEvoy, {Joseph Patrick} and Scott Stroup",
year = "2015",
month = "7",
day = "1",
doi = "10.1097/NMD.0000000000000317",
language = "English (US)",
volume = "203",
pages = "486--492",
journal = "Journal of Nervous and Mental Disease",
issn = "0022-3018",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Randomized trial of the effect of four second-generation antipsychotics and one first-generation antipsychotic on cigarette smoking, alcohol, and drug use in chronic schizophrenia

AU - Mohamed, Somaia

AU - Rosenheck, Robert A.

AU - Lin, Haiqun

AU - Swartz, Marvin

AU - McEvoy, Joseph Patrick

AU - Stroup, Scott

PY - 2015/7/1

Y1 - 2015/7/1

N2 - No large-scale randomized trial has compared the effect of different second-generation antipsychotic drugs and any first-generation drug on alcohol, drug and nicotine use in patients with schizophrenia. The Clinical Antipsychotic Trial of Intervention Effectiveness study randomly assigned 1432 patients formally diagnosed with schizophrenia to four second-generation antipsychotic drugs (olanzapine, risperidone quetiapine, and ziprasidone) and one first-generation antipsychotic (perphenazine) and followed them for up to 18 months. Secondary outcome data documented cigarettes smoked in the past week and alcohol and drug use severity ratings. At baseline, 61% of patients smoked, 35% used alcohol, and 23% used illicit drugs. Although there were significant effects of time showing reduction in substance use over the 18 months (all p < 0.0001), this study found no evidence that any antipsychotic was robustly superior to any other in a secondary analysis of data on substance use outcomes from a large 18-month randomized schizophrenia trial.

AB - No large-scale randomized trial has compared the effect of different second-generation antipsychotic drugs and any first-generation drug on alcohol, drug and nicotine use in patients with schizophrenia. The Clinical Antipsychotic Trial of Intervention Effectiveness study randomly assigned 1432 patients formally diagnosed with schizophrenia to four second-generation antipsychotic drugs (olanzapine, risperidone quetiapine, and ziprasidone) and one first-generation antipsychotic (perphenazine) and followed them for up to 18 months. Secondary outcome data documented cigarettes smoked in the past week and alcohol and drug use severity ratings. At baseline, 61% of patients smoked, 35% used alcohol, and 23% used illicit drugs. Although there were significant effects of time showing reduction in substance use over the 18 months (all p < 0.0001), this study found no evidence that any antipsychotic was robustly superior to any other in a secondary analysis of data on substance use outcomes from a large 18-month randomized schizophrenia trial.

KW - Alcohol dependence

KW - Drug dependence

KW - Schizophrenia

KW - Second-generation antipsychotics

KW - Smoking

UR - http://www.scopus.com/inward/record.url?scp=84941061004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941061004&partnerID=8YFLogxK

U2 - 10.1097/NMD.0000000000000317

DO - 10.1097/NMD.0000000000000317

M3 - Article

VL - 203

SP - 486

EP - 492

JO - Journal of Nervous and Mental Disease

JF - Journal of Nervous and Mental Disease

SN - 0022-3018

IS - 7

ER -